Type 2 Diabetes Mellitus
Conditions
Keywords
Glucagon-like peptide-1, Glucose-dependant insulinotropic polypeptide, Glucagon, Peptide PYY, 2-oleyl glycerol
Brief summary
Activation of G protein-coupled receptor GPR119 stimulates glucagon-like peptide-1 (GLP-1)release from the intestinal L-cells. Previously, administration of 2-oleyl-glycerol (2-OG) to humans significantly increased plasma GLP-1. In the present study we want to test the effect in patients with type 2 diabetes. The hypothesis is that we will expect to find a significant increased plasma GLP-1 following a meal containing of 2-OG when compared to meals containing of olive oil or carbohydrates alone.
Detailed description
Activation of G protein-coupled receptor GPR119 stimulates glucagon-like peptide-1 (GLP-1)release from the intestinal L-cells. Previously, administration of 2-oleyl-glycerol (2-OG) to humans significantly increased plasma GLP-1. In the present study we want to test the effect in patients with type 2 diabetes. The hypothesis is that we will expect to find a significant increased plasma GLP-1 following a meal containing of 2-OG when compared to meals containing of olive oil or carbohydrates alone. The aim of the study is to elucidate the effect of 2-OG, 'diet oil' on GLP-1 secretion in patients with type 2 diabetes and to explain the mechanism behind the known stimulation of GLP-1 release by dietary fat.
Interventions
DIETARY_SUPPLEMENTDiet oil
Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
DIETARY_SUPPLEMENTOlive oil
Carrot and olive oil and 1½ g of paracetamol
DIETARY_SUPPLEMENTCarrot
Carrot and 1½ g of paracetamol
Sponsors
University of Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with type 2 diabetes mellitus according to the WHO criteria * caucasians * age above 18 years * BMI 20-30
Exclusion criteria
* kidney disease * liver disease * retinopathy * anaemia * use of insulin * use of GLP-1 analogues * use of DPP-4 inhibitors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma GLP-1 | 3 hours | Glp-1 response is measured during and three hours after ingestion of the different mealtest |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma insulin | 3 hours | Plasma insulin is measured during and 3 hours after mealtest |
| Plasma glucose | 3 hours | Plasma glucose is measured during and 3 hours after meal test |
| Plasma GIP | 3 hours | Plasma GIP is measured during and 3 hours after meal test |
| Plasma PYY | 3 hours | Plasma PYY is measured during and 3 hours after meal test |
| Plasma paracetamol | 3 hours | Plasma paracetamol is measured during and 3 hours after meal test |
| Plasma glucagon | 3 hours | Plasma glucagon is measured during and 3 hours after meal test |
Countries
Denmark
Outcome results
None listed